Catalog No.
Product Name
Application
Product Information
Citations
-
GABAAR Antagonist
GMQ is a competitive antagonist of the GABAergic receptor, primarily targeting the GABA(A) receptor subtypes α1β2, α1β2γ2, α4β2γ2, and α5β2γ2. This compound potently inhibits GABAAR activity, enhancing neuronal excitation by disrupting GABAergic transmission. Additionally, GMQ offers anti-histaminic effects within the enteric system, specifically inhibiting gastric acid secretion, making it valuable for research in neuropharmacology and gastrointestinal function. -
GABA Receptor Antagonist
GABAB receptor antagonist 3 is a potent inhibitor of the GABAB receptor, which plays a crucial role in neurotransmission and modulation of synaptic activity. This compound effectively blocks GABAB receptor signaling, making it valuable for studying the physiological and pathological roles of GABA in the central nervous system. Its applications include research into anxiety, epilepsy, and other neuropsychiatric disorders, providing insights into potential therapeutic interventions. -
GABAA Agonist
DS1 is a potent agonist of the GABAA receptor, enhancing its activity. This compound stimulates serum response element (SRE) and cAMP response element (CRE) promoters, leading to increased expression of luteinizing hormone beta (LHbeta) and follicle-stimulating hormone beta (FSHbeta) genes. DS1 is valuable for research applications focused on the modulation of GABAA receptor activity and its effects on hormone regulation. -
Tuclazepam
Tuclazepam is a benzodiazepine derivative primarily targeting the central nervous system to exert its anxiolytic and sedative effects. This compound is utilized in research focused on anxiety disorders and sleep-related studies due to its ability to modulate GABA receptor activity. Its significant calming properties make Tuclazepam an important reagent for investigating the neuropharmacological mechanisms underlying anxiety and sedation. -
GABAB Receptor Agonist
CGP47656 is a potent GABAB receptor agonist that selectively inhibits forskolin-stimulated adenylyl cyclase activity while enhancing noradrenaline-stimulated adenylyl cyclase activity. This compound is valuable for investigating the role of GABAB receptors in various neurological functions and diseases, offering potential insights into therapeutic strategies for brain function-related disorders. Its unique mechanism of action makes it a useful tool for researchers studying synaptic transmission and neuropharmacology. -
GABA Receptor Agonist
(R)-Baclofen hydrochloride is a selective agonist of the GABAB receptor. This compound is primarily utilized for its muscle relaxant properties and has been studied for its potential therapeutic effects in conditions such as spasticity and pain management. Its mechanism of action involves the modulation of neurotransmitter release, thereby influencing synaptic transmission and muscle tone. Research applications include neuroscience studies and investigations into GABAB receptor pathways. -
GABAB Receptor Antagonist
CGP 62349 is a selective GABAB receptor antagonist that exhibits oral bioactivity. This compound has been shown to enhance cognitive performance across various learning paradigms, making it a valuable tool in neuroscience research. Its application can provide insights into the modulation of cognitive processes and the therapeutic potential for cognitive impairments. -
GABA Antagonist
CGS-9895 is a GABA antagonist that functions by binding to the benzodiazepine site on GABA receptors. This compound selectively inhibits the activity of GABA, a major inhibitory neurotransmitter in the central nervous system. Its application in research includes studies on anxiety, depression, and seizure disorders, providing insights into the modulation of GABAergic signaling. -
GABAA receptors agonist
JY-XHe-053 is a selective agonist of GABAA receptors, particularly targeting those containing the α5 subunit, with an affinity of 0.7 nM. This compound demonstrates significant biological activity at GABAA receptors, particularly at the α2 and α3 subunits. Despite its potency, JY-XHe-053 exhibits minimal anti-anxiety activity, making it a valuable tool for investigating GABAA receptor function and the role of the α5 subunit in neurological research. -
GABAA Receptor Agonist
PF-0713 is a selective agonist of the GABAA receptor, which plays a crucial role in inhibitory neurotransmission within the central nervous system. This compound exhibits significant anxiolytic and anticonvulsant properties, making it valuable for research in neuropharmacology and potential therapeutic applications in anxiety disorders and epilepsy. PF-0713's mechanism of action can aid in understanding GABAA receptor modulation and its implications in various neurological conditions. -
GABAR RDL Antagonist
Chrodrimanin B is a potent antagonist of the GABA receptor RDL, primarily sourced from a fungal metabolite. It effectively inhibits GABA-mediated responses with an IC50 of 1.66 nM, demonstrating a peak current amplitude reduction at the RDL channel with an IC50 of 1.13 nM. This meroterpenoid compound exhibits significant insecticidal activity, making it a valuable tool in the study of insect neurobiology and potential pest control applications. -
GABAA Receptor Ligand
PNU-107484A is a selective GABAA receptor ligand with distinct activity across various α isoform subtypes. It functions as a positive allosteric modulator for the α1β2γ2 subtype, enhancing GABA-induced chloride currents, while exhibiting inhibitory effects on the α3β2γ2 and α6β2γ2 subtypes. The compound demonstrates half-maximal inhibitory concentrations of 3.1 μM for α1β2γ2, 4.2 μM for α3β2γ2, and 3.5 μM for α6β2γ2. PNU-107484A serves as a valuable tool for exploring the physiological implications of different GABAA receptor α isoform subtypes in research settings. -
GABA/nACh Receptor Inhibitor
APS3 is a potent inhibitor of GABA and nicotinic acetylcholine (nACh) receptors, showcasing a lethal concentration (LC50) of 7.2423 μg/mL against the pest Plutella xylostella. This compound is useful for studying neuropharmacological pathways and assessing the impact of receptor inhibition on insect behavior and survival. Applications include research in insect physiology and the development of pest management strategies. -
Insecticide
Insecticidal agent 21 is a potent insecticide primarily targeting Culex pipiens larvae with an LC50 of 0.4 μg/mL. This compound exerts multi-target neurotoxicity by inhibiting acetylcholinesterase (AChE) and affecting multiple neural receptors, including nicotinic acetylcholine receptors (nAChR), voltage-gated sodium channels (VGSC), and γ-aminobutyric acid receptors (GABAAR). Insecticidal agent 21 demonstrates a strong insecticidal effect and is suitable for research applications focused on developing novel insecticides to combat resistance in mosquito populations. -
GABAA Receptor Antagonist
SKF 10810 is a GABAA receptor antagonist with an EC50 of 4.3 μM, demonstrating a notable capacity to inhibit GABAergic signaling. By disrupting GABA-mediated inhibition in reward pathways of the brain, SKF 10810 may have potential antidepressant effects. This compound serves as a valuable tool for research into neurological disorders and the mechanisms underlying mood regulation. -
GABA/GHBR Antagonist
NCS-382 is a potent antagonist of the GABA and GHBR receptors. It exhibits significant anticonvulsant and antisedative properties, making it a valuable reagent for studying neurological disorders. NCS-382 is primarily utilized in research related to hereditary nervous system diseases, providing insights into the mechanisms underlying these conditions. -
Benzodiazepine Agonist
Adinazolam mesylate is a triazolobenzodiazepine that functions as a benzodiazepine agonist. It exerts its biological activity by allosterically binding to peripheral-type benzodiazepine receptors, which modulate GABA receptor function. This compound demonstrates dual anxiolytic and antidepressant effects, making it a valuable tool in research focused on anxiety and depression-related pathways. -
Atagabalin Stereoisomer
iso-Atagabalin hydrochloride is a stereoisomer of Atagabalin, functioning primarily as a selective GABA (gamma-aminobutyric acid) receptor agonist. It is noted for its antianxiety effects, making it a valuable tool for research focused on anxiety disorders and related neurological conditions. This compound can aid in elucidating the mechanisms of GABAergic modulation in various biological contexts. -
GABA Receptor Modulator
SGE-516 is a neuroactive steroid functioning as a potent positive allosteric modulator of both synaptic and extra-synaptic GABAA receptors. This compound exhibits significant anticonvulsant activity, making it a valuable tool for research in neurological disorders, especially those related to GABAergic signaling. Its modulatory effects can provide insights into therapeutic strategies for epilepsy and other conditions characterized by altered GABA receptor function. -
GABA Aminotransferase Inhibitor
Gabaculine is a potent inhibitor of GABA aminotransferase, an enzyme responsible for the degradation of gamma-aminobutyric acid (GABA). This compound, derived from the microbial strain Streptomyces toyocaensis, effectively increases GABA levels, thereby modulating neurotransmission and exhibiting potential anxiolytic effects. Gabaculine is widely utilized in neurobiological research to study neurotransmitter dynamics and the role of GABA in various neurological disorders. -
GABAA Receptor Partial Agonist
ELB-139 is a GABAA receptor partial agonist known for its anxiolytic and anticonvulsant properties. This progesterone analogue modulates GABAA receptor activity, demonstrating significant effects on neurotransmitter levels, particularly enhancing extracellular serotonin (5-HT) in the striatum and medial prefrontal cortex of rodent models. ELB-139 holds potential for research applications related to anxiety disorders and seizure disorders. -
GABA Receptor
Epi-Aszonalenin A is a benzodiazepine fungal metabolite that targets the GABA receptor. It exhibits psychoactive properties, making it a valuable compound for studying the modulation of neurotransmission and its effects on behavior. This compound has potential applications in neuroscientific research related to anxiety, sedation, and other disorders associated with GABAergic signaling. -
GABA Receptor
Carburazepam is a benzodiazepine derivative that targets GABA receptors, enhancing the inhibitory neurotransmitter's effects within the central nervous system. Its primary biological activity includes anxiolytic and sedative properties, making it useful in research related to anxiety disorders and sleep disturbances. As a research reagent, Carburazepam provides valuable insight into the pharmacological mechanisms of benzodiazepines and their impact on neuronal signaling pathways. -
GABA Receptor
Suclofenide is an anticonvulsant compound that modulates GABA receptor activity, influencing GABA metabolism. It exhibits potential neuroprotective effects and has been utilized in research related to epilepsy and seizure disorders. Suclofenide serves as a valuable tool for investigating GABAergic signaling and its implications in various neurological conditions. -
GABA Receptor
CGP11952 is a triazolyl-benzophenone that acts as a positive allosteric modulator of the GABA receptor. This compound exhibits characteristics similar to benzodiazepines, contributing to its pharmacological profile. CGP11952 is primarily utilized in research to investigate GABAergic signaling and its implications in neurological disorders. -
GABA Receptor Agonist
Ro 41-3290 is a selective GABA receptor agonist, acting primarily as a partial agonist at the benzodiazepine site. This compound demonstrates potent biological activity in modulating GABAergic neurotransmission, making it valuable for research in the fields of neuropharmacology and anxiety disorders. Its mechanisms may provide insights into therapeutic approaches for conditions such as anxiety, insomnia, and seizure disorders. -
GABA Receptor Agonist
FG8119 is a novel benzodiazepine agonist that targets GABA receptors, enhancing their activity. This compound demonstrates significant anxiolytic and sedative effects, making it valuable for research in neuropharmacology and the study of anxiety disorders. FG8119 can be utilized to investigate the modulation of GABAergic neurotransmission and its implications in various neurological conditions. -
Glycine/NMDA Receptor Antagonist
ZD 9379 sodium acts as a competitive antagonist at the glycine-binding site of the NMDA receptor, exhibiting an IC50 value of 75 nM for the glutamate site. This compound inhibits glycine binding, mitigating excitotoxicity and demonstrating therapeutic potential in conditions such as acute ischemic stroke. ZD 9379 sodium reduces the frequency of cortical spreading depression, decreases infarct volume, and enhances neurological function in preclinical mouse models, making it a valuable tool for research in neuroprotection and stroke mechanisms. -
Positive Allosteric Modulator Of GluN1/GluN3 NMDA Receptors
UCM-A86 is a selective positive allosteric modulator of the GluN1/GluN3 NMDA receptors, exhibiting EC50 values of 21 µM and 19 µM for GluN1/GluN3A and GluN1/GluN3B receptors, respectively. This compound preferentially enhances signaling through GluN1/GluN3A/B receptors while displaying minimal activity at GluN1/GluN2A-D receptors. UCM-A86 serves as a valuable tool for research focused on central nervous system disorders and the modulation of NMDA receptor activity. -
NMDA Receptor Antagonist
Dizocilpine is a potent, non-competitive antagonist of the NMDA receptor, characterized by a Kd of 37.2 nM in rat brain membranes. By binding to a specific site within the NMDA-associated ion channel, it effectively inhibits calcium ion (Ca2+) influx. This compound is widely used in research focused on epilepsy, neurotoxicity, and neurodegenerative diseases, making it a valuable tool for studying excitotoxicity and synaptic function. -
NMDA Receptor Antagonist
Cycloleucine is a selective NMDA receptor antagonist that targets the glycine site, exhibiting a Ki value of 600 μM. This compound inhibits S-adenosyl-methionine-mediated methylation and acts as a competitive inhibitor of ATP: L-methionine-S-adenosyl transferase in vitro. Cycloleucine demonstrates anxiolytic and cytostatic properties, making it a valuable tool for research in neurobiology and cancer studies. Its unique mechanism of action provides insights into the underlying pathways of excitotoxicity and cellular regulation. -
NMDA Receptor Antagonist
5,7-Dichlorokynurenic acid (5,7-DCKA) is a selective and competitive antagonist of the glycine binding site on the NMDA receptor, exhibiting a KB value of 65 nM. This compound effectively reduces NMDA-induced neuronal injury and enhances social interaction and exploration behaviors in rodent models. Additionally, 5,7-DCKA demonstrates anxiolytic-like effects, facilitating research into the role of glycine in NMDA receptor-mediated synaptic activity and associated psychiatric disorders. -
NMDAR Agonist
N,N-Dimethylglycine is a natural N-methylated glycine that serves as a partial agonist at the N-methyl-D-aspartate receptor (NMDAR) glycine site. It functions as a methyl donor, enhancing immune response and exhibiting antioxidant properties to mitigate oxidative stress by scavenging free radicals. Additionally, N,N-Dimethylglycine has demonstrated antidepressant-like effects and surfactant activity, making it valuable for various research applications in neuropharmacology and immunology. -
NMDA Antagonist
Orphenadrine is a skeletal muscle relaxant that acts as an NMDA antagonist, primarily inhibiting the binding of [3H]MK-801 to the PCP binding site of the NMDA receptor. This compound exhibits a range of biological activities including antiparkinsonian, antihistaminic, antitremor, antispasmodic, and analgesic effects. Additionally, Orphenadrine has been shown to induce oxidative stress through CAR nuclear translocation and may have implications in pro-tumor activities. It also demonstrates neuroprotective properties by safeguarding rat cerebellar granule cells from 3-NPA-induced cytotoxicity, suggesting potential therapeutic applications in neurodegenerative diseases associated with NMDA receptor overactivation. -
FLNA Modulator
Simufilam hydrochloride is an orally active modulator of filamin A (FLNA) that targets neuronal signaling pathways. This compound restores NMDAR signaling and Arc expression while inhibiting dysregulated mTOR activity. Additionally, it enhances insulin sensitivity and mitigates Aβ42-induced neuroinflammation and tau protein hyperphosphorylation. Simufilam hydrochloride is applicable in research related to Alzheimer's disease, particularly in understanding the underlying mechanisms of neurodegeneration. -
Gly/NMDA Receptor Antagonist
CGP 78608 hydrochloride is a highly potent and selective antagonist at the glycine-binding site of the NMDA receptor, exhibiting an IC50 of 6 nM. This compound acts as a potentiator of GluN1/GluN3A-mediated glycine currents, with an estimated EC50 in the low nM range (26.3 nM). CGP 78608 hydrochloride is primarily employed in research investigating its anticonvulsant activity and the modulation of excitatory neurotransmission. -
NMDA Receptor Agonist
L-Homocysteic acid is an endogenous excitatory amino acid functioning as a NMDA receptor agonist, with an effective concentration (EC50) of 14 μM. Its neurotoxic properties make it a valuable tool in the investigation of neurological disorders. L-Homocysteic acid enables researchers to explore the roles of excitatory neurotransmission and contribute to the understanding of related pathophysiological conditions. -
NMDA Receptor PAM
Plazinemdor is a positive allosteric modulator of the N-methyl-D-aspartate (NMDA) receptor. This compound enhances NMDA receptor activity, making it a valuable tool for investigating its role in psychiatric, neurological, and neurodevelopmental disorders. Plazinemdor is suitable for research applications focused on understanding the underlying mechanisms of various nervous system diseases. -
NMDA Antagonist
Fluoroethylnormemantine is an N-methyl-D-aspartate (NMDA) receptor antagonist, serving as a derivative of Memantine. This compound showcases neuroprotective, anti-amnesic, and antidepressant-like properties, making it valuable in neurological research. Additionally, [18F]-Fluoroethylnormemantine is utilized as a positron emission tomography (PET) tracer, enhancing imaging studies related to NMDA receptor activity and its implications in various mental health disorders. -
NMDA Receptor Inhibitor
Pregnanolone sulfate (pyridinium) is an endogenous neurosteroid that functions as an inhibitor of NMDA receptors. This compound exhibits neuroprotective properties, making it a valuable tool for investigating neurodegenerative disorders and synaptic plasticity. Its ability to modulate excitatory neurotransmission highlights its potential applications in both basic research and therapeutic development. -
NMDA Receptor Modulator
Rapastinel Trifluoroacetate is a modulator of the NMDA receptor, functioning as a partial agonist at the glycine site. This compound has shown potential for the treatment of major depressive disorder, contributing to neuroplasticity and synaptic function. It is utilized in research exploring depression and related neurological conditions, providing insights into the therapeutic effects of NMDA receptor modulation. -
NMDA Agonist
Cis-Piperidine-2,3-dicarboxylic acid primarily targets NMDA receptors and acts as a partial agonist. This compound is known for its ability to block general excitatory synaptic transmission by interfering with NMDA, AMPA, and kainate ionotropic receptors. Cis-Piperidine-2,3-dicarboxylic acid is valuable for research applications related to neuropharmacology and the study of synaptic plasticity. -
NMDAR Allosteric Modulator
GNE-9278 is a selective positive allosteric modulator of the N-methyl-D-aspartate receptor (NMDAR), targeting the GluN1 transmembrane domain. It enhances peak current and agonist affinity in activated NMDARs, offering potential insights into synaptic transmission and plasticity. This compound is valuable for research investigating NMDAR-related neurological disorders and synaptic function. -
NMDA Receptor Partial Agonist
Zelquistinel (AGN-241751) is a potent orally active partial agonist of the N-methyl-D-aspartate (NMDA) receptor. It has demonstrated significant biological activity relevant to the research of neuropsychiatric conditions, including depression and anxiety. Zelquistinel serves as a valuable tool for studying the pharmacological mechanisms underlying these disorders and evaluating potential therapeutic interventions. -
GluN2B-NMDAR Antagonist
GluN2B-NMDAR antagonist-1 is an orally active antagonist of the GluN2B subtype of the N-methyl-D-aspartate receptor (NMDAR). This compound exhibits neuroprotective properties, making it a valuable tool in studying ischemic injury and related neurodegenerative conditions. It is primarily used in research to explore mechanisms of neuronal damage and potential therapeutic interventions. -
FLNA Modulator
Simufilam is an orally active modulator of filamin A (FLNA) that restores NMDA receptor (NMDAR) signaling and Arc expression. It effectively inhibits overactive mTOR signaling by restoring the normal conformation of FLNA, which results in improved insulin sensitivity and a reduction in Aβ42-induced neuroinflammation and tau protein hyperphosphorylation. This compound is particularly valuable for research applications focused on Alzheimer's disease and related neurodegenerative disorders. -
NMDA Receptor Antagonist
Co 101244 hydrochloride is a selective antagonist of the NMDA receptor, specifically targeting the NR2B subunit. This compound is utilized in research to investigate the role of NMDA receptors in synaptic plasticity, neurodegeneration, and various neurological disorders. Its properties make it a valuable tool for studying excitatory neurotransmission and the mechanisms underlying synaptic function. -
Acetylcholinesterase Inhibitor, Butyrylcholinesterase Inhibitor, Carbonic Anhydrase I/II Inhibitor, α-Glycosidase Inhibitor
Vescalagin is a hexahydroxyphenol that acts as an inhibitor of acetylcholinesterase and butyrylcholinesterase, as well as carbonic anhydrases I and II, and α-glycosidase. It demonstrates potent inhibitory activity with Ki values of 5.87 nM for AChE, 3.89 nM for BChE, 11.75 nM for hCA I, 16.23 nM for hCA II, and 16.08 nM for α-glycosidase. Vescalagin exhibits non-competitive inhibition for hCA I, hCA II, and α-glycosidase, while also reducing hyperglycemia and hypertriglyceridemia in dietary models. Additionally, it possesses anti-inflammatory and antioxidant activities, making it a valuable compound for research in diabetes and metabolic disorders. -
NMDA Receptor Inhibitor
Bupivacaine is an NMDA receptor inhibitor that modulates neuronal excitability by blocking sodium, L-calcium, and potassium channels. It exhibits potent inhibition of SCN5A channels, with an IC50 of 69.5 μM. This compound is primarily utilized in research focused on chronic pain mechanisms and therapeutic interventions. -
Stable Isotope
Acetylcholine-d4 chloride is a deuterium-labeled form of the neurotransmitter acetylcholine. It functions as a potent cholinergic agonist and effectively crosses the blood-brain barrier (BBB). This reagent modulates dopaminergic neuronal activity by stimulating nicotinic acetylcholine receptors (nAChRs) and has also been shown to inhibit the aggregation of p53 mutant peptides in vitro. Its unique isotopic labeling makes it a valuable tool for chemical and biological research applications.
